Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$9.4M, compared with $1.03M a year earlier. Trailing-twelve-month accounts receivables was -$9.33M.
Context
- Accounts receivables amounted to 2.2% of revenue in FY2025, down 5.7 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$9.4M or moves back toward the trailing-twelve-month quarterly average of -$2.33M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.09M USD
- Year-over-year change
- +144.2%
- 4-year CAGR
- +30.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.09M | +144.2% |
| FY2024 | 2024-12-31 | (2.46M) | -150.8% |
| FY2023 | 2023-12-31 | (982K) | -6914.3% |
| FY2022 | 2022-12-31 | (14K) | -103.7% |
| FY2021 | 2021-12-31 | 381K | — |
Accounts Receivables vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 accounts receivables of $9.33M is the 5th largest of the 11 companies compared; the peer median is $24.87K.
- Its year-over-year change of +913.2% is the highest of 7, against a peer median of -42.7%.
- Accounts receivables amounts to 13.4% of revenue for LXRX, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $63.73M | -14.2% | -10.4% | 6.6% | |
| LTM Jun 2026 | $44.38M | -720.6% | -40.6% | 4.4% | |
| LTM Mar 2026 | $22.62M | +351.7% | -26.1% | 6.3% | |
| LTM Jun 2026 | $17.47M | -45.2% | +19.7% | 1.9% | |
| LTM Mar 2026 | $9.33M | +913.2% | — | 13.4% | |
| LTM Mar 2026 | $8.4M | -40.2% | -25.8% | 2.8% | |
| LTM Mar 2026 | $49.73K | -134.1% | — | — | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding LXRX) | $24.87K | -42.7% | -25.8% | 3.6% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| Deferred Income Tax | 49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.58M | 11.52M | 14.34M | 13.5M | 12.52M |
| Change in Working Capital | (10.23M) | 402K | 2.66M | 14.24M | (26.89M) |
| Accounts Receivables | 381K | (14K) | (982K) | (2.46M) | 1.09M |
| Inventory | 0 | 0 | (381K) | 150K | (50K) |
| Accounts Payables | (14.16M) | 76K | 6.45M | 14.8M | (30.22M) |
| Other Working Capital | 3.55M | 340K | (2.43M) | 1.75M | 2.29M |
| Other Non-Cash Items | 54K | 744K | (2.33M) | (6.65M) | (3.75M) |
| Operating Cash Flow | (87.02M) | (88.85M) | (161.9M) | (178.78M) | (67.85M) |
| Capital Expenditures | (1.22M) | (1.33M) | (470K) | (1.03M) | 0 |
| Acquisitions (Net) | (3.33M) | 69.75M | 0 | 0 | 0 |
| Purchases of Investments | (34.26M) | (133.95M) | (223.34M) | (338.05M) | (143.55M) |
| Sales of Investments | 37.59M | 64.2M | 173.87M | 314.4M | 252.86M |
| Other Investing Activities | 3.33M | (69.75M) | 0 | 9.31M | 3.71M |
| Investing Cash Flow | 2.11M | (71.08M) | (49.94M) | (15.38M) | 113.02M |
| Debt Repayment | (11.7M) | 48.87M | 49.96M | 0 | (48M) |
| Common Stock Issued | 37.08M | 94.21M | 138.82M | 64K | 73K |
| Common Stock Repurchased | (2.68M) | (864K) | (824K) | (1.73M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 94.21M | 0 | (1.24M) | (572K) |
| Financing Cash Flow | 22.71M | 142.21M | 187.96M | 238.35M | (48.5M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (62.2M) | (17.72M) | (23.88M) | 44.19M | (3.33M) |
| Free Cash Flow | (88.24M) | (90.18M) | (162.37M) | (179.81M) | (67.85M) |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.